Nektar Therapeutics (NASDAQ:NKTR) has a beta value of 0.67 and has seen 0.84 million shares traded in the recent trading session. The company, currently valued at $184.46M, closed the recent trade at $1.00 per share which meant it gained $0.02 on the day or 1.77% during that session. The NKTR stock price is -93.0% off its 52-week high price of $1.93 and 37.0% above the 52-week low of $0.63. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.31 million shares traded. The 3-month trading volume is 2.20 million shares.
The consensus among analysts is that Nektar Therapeutics (NKTR) is Buy stock at the moment, with a recommendation rating of 2.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.19.
Nektar Therapeutics (NASDAQ:NKTR) trade information
Sporting 1.77% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the NKTR stock price touched $1.00 or saw a rise of 7.41%. Year-to-date, Nektar Therapeutics shares have moved 7.53%, while the 5-day performance has seen it change 42.86%. Over the past 30 days, the shares of Nektar Therapeutics (NASDAQ:NKTR) have changed 12.15%. Short interest in the company has seen 5.76 million shares shorted with days to cover at 3.91.
Wall Street analysts have a consensus price target for the stock at $18.5, which means that the shares’ value could jump 94.59% from the levels at last check today. The projected low price target is $6.0 while the price target rests at a high of $24.0. In that case, then, we find that the latest price level in today’s session is -2300.0% off the targeted high while a plunge would see the stock gain -500.0% from the levels at last check today.
Nektar Therapeutics (NKTR) estimates and forecasts
The company’s shares have lost -15.97% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 17.53%.
9 analysts offering their estimates for the company have set an average revenue estimate of 36.65M for the current quarter. 6 have an estimated revenue figure of 22.39M for the next ending quarter. Year-ago sales stood 23.89M and 21.64M respectively for this quarter and the next, and analysts expect sales will grow by 53.46% for the current quarter and 17.53% for the next.
Earnings growth for 2025 is a modest 50.60% while over the next 5 years, the company’s earnings are expected to increase by 21.38%.
NKTR Dividends
Nektar Therapeutics is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Nektar Therapeutics (NASDAQ:NKTR)’s Major holders
Insiders own 1.30% of the company shares, while shares held by institutions stand at 72.54% with a share float percentage of 73.50%. Investors are also buoyed by the number of investors in a company, with Nektar Therapeutics having a total of 180.0 institutions that hold shares in the company. The top two institutional holders are DEEP TRACK CAPITAL, LP with over 17.88 million shares worth more than $22.17 million. As of 2024-06-30, DEEP TRACK CAPITAL, LP held 9.1789% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 15.16 million shares as of 2024-06-30. The firm’s total holdings are worth over $18.79 million and represent 7.7823% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Vanguard Total Stock Market Index Fund. As of Sep 30, 2024, the former fund manager holds about 5.10% shares in the company for having 9.4 shares of worth $9.3 million while later fund manager owns 5.72 shares of worth $5.66 million as of Sep 30, 2024, which makes it owner of about 3.10% of company’s outstanding stock.
